Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress Urged To Address Expanded OMB Role In Regulations, Guidances

Executive Summary

The government watchdog group OMB Watch is urging Congress to take action against an executive order that increases the administration's influence over regulations and guidance documents issued by FDA and other agencies

You may also be interested in...

Executive order “defunded”

The House moves to block funding for Executive Order 13422, which would increase Office of Management and Budget oversight over all federal agencies, with legislation passed June 28. Among other things, the order states that OMB has the authority to require notice and review of agency guidance documents (1"The Tan Sheet" Jan. 29, 2007, In Brief). An amendment to an appropriations bill (HR 2829) passed by the House stipulates that "none of the funds made available by this act may be used to implement" the executive order. The bill provides funding for the Treasury Department, Executive Office and general government activities. The amendment was co-sponsored by Science Subcommittee on Oversight Chair Brad Miller, D-N.C., and Judiciary Subcommittee on Commercial and Administrative Law Chair Linda Sanchez, D-Cal., who each held hearings on the executive order in February (2"The Tan Sheet" March 12, 2007, p. 10). No similar action has been taken as yet in the Senate...

Political Oversight Of Agency Guidances, Rules Slated For House Hearing

Two House subcommittees are planning a joint hearing on amended 1Executive Order 12866, which institutionalizes the review of federal agency regulations and guidance documents by presidential appointees rather than career agency staff

Nuvasive Grows Bone Graft Basket For Spinal Fusion

The San Diego firm is diversifying its spinal fusion offerings with a $16 million purchase of the Formagraft synthetic bone graft product line.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts